Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
AGS-v PLUS by Imutex for Zika Virus Infections: Likelihood of Approval
AGS-v PLUS is under clinical development by Imutex and currently in Phase I for Zika Virus Infections. According to GlobalData,...
Data Insights
AGS-v PLUS by Imutex for West Nile Encephalitis (West Nile Fever): Likelihood of Approval
AGS-v PLUS is under clinical development by Imutex and currently in Phase I for West Nile Encephalitis (West Nile Fever)....